Melatonin and Children

Melatonin is the pineal hormone that signals biological night — a chronobiotic that shifts sleep timing rather than a sedative that forces sleep — and its regulatory status is the whole controversy in miniature: prescription-only medicine for children across the UK, EU and Australia; an unregulated dietary supplement in the US and Canada, sold as fruit-flavoured gummies beside the vitamins. The consequences of the supplement route are measured, not hypothetical: independent testing found gummy products containing from 74% to 347% of labelled melatonin — one contained none at all (it was CBD) — because no pre-market verification exists; paediatric usage surged (parent-reported use in nearly one in five US school-age children in recent surveys); and the accidental-ingestion curve followed the gummies into the home. This hub's doctrine is not that melatonin is dangerous — it is that a hormone with real effects, real uses and unknown developmental questions acquired the safety oversight of a jelly bean.

The surveillance record is the hub's hardest data. US poison-centre calls for paediatric melatonin exposures rose over 500% across a decade (2012-2021), making melatonin the most frequently ingested substance in young-child poison reports; CDC analysis logged roughly 11,000 emergency-department visits for unsupervised melatonin ingestion by infants and young children in four years (2019-2022) — gummies implicated in about half, half of cases in 3-5-year-olds, and three-quarters involving bottles the children opened or that were left open; Australian poison lines report a parallel doubling. The clinical reassurance and its limit: acute melatonin overdose is rarely dangerous (drowsiness, GI upset dominate; hospitalisations a small fraction, deaths vanishingly rare) — but rarely-dangerous multiplied across an uncontrolled candy-format market still bought thousands of ED visits, and industry's response has been voluntary (child-resistant packaging and dose-verification pledges from 2024) rather than mandated. The fix is packaging, storage and format — the tractable half of this topic.

Melatonin's paediatric evidence is genuine and specific. Best supported: children with autism spectrum conditions and ADHD, where sleep-onset problems are prevalent and trials (including the licensed paediatric prolonged-release product in Europe) show meaningfully faster sleep onset and longer sleep — the population for which prescription frameworks exist; and circadian applications (delayed sleep phase in adolescents, blindness-related rhythm disorders) where low-dose, correctly-timed melatonin is working with its actual mechanism. Modestly supported: short-term use for sleep-onset insomnia in neurotypical children — trials show sleep onset advanced by roughly 15-30 minutes, a real but unspectacular effect. Not supported: the pattern the market created — indefinite nightly gummies as a routine sleep aid for ordinary behavioural sleep problems, which trials never tested at the durations families now use, and which paediatric sleep medicine unanimously ranks behind the intervention with the strongest evidence and no dose-verification problem: behavioural sleep treatment (consistent schedules, stimulus control, limit-setting), which outperforms or matches melatonin in the ordinary-child scenarios where most gummies are actually consumed.

The honest uncertainty at the file's centre: melatonin is not just a sleep signal — it participates in circadian and seasonal biology that, in other mammals, regulates reproductive timing, and pharmacological doses in children produce blood levels far above physiological night. Long-term randomised safety data in developing children essentially do not exist; the observational reassurance (decades of prescribed use in autistic children without obvious pubertal signals, small follow-up studies finding no clear effect on pubertal timing) is genuinely reassuring and genuinely weak — small samples, short horizons, no trials designed for the question. European regulators' prescription-gating reflects exactly this posture: probably fine, insufficiently proven, therefore supervised. The parallel uncertainty is dosing: physiological signalling needs fractions of a milligram, gummies deliver 1-10 mg (before the 74-347% lottery), and the market's dose inflation has no evidentiary basis — lower is mechanistically sounder for timing effects. None of this is alarm; all of it is the difference between a hormone and a vitamin, which the gummy format erases.

Melatonin-and-kids is the collection's cleanest specimen of a familiar machine aimed at parents: a real problem (up to a quarter of children have behavioural sleep difficulties; exhausted parents are the most motivated buyers in retail), a grain of real science (the autism/ADHD and circadian evidence above), a format engineered for compliance (candy), influencer-and-algorithm distribution ("magic gummies" content), and the substitution harm — the evidence-backed intervention (behavioural treatment: unglamorous, effortful, free) displaced by the purchasable one, while the underlying drivers (screens in bedrooms, evening light, inconsistent schedules, caffeine creep into childhood via the adjacent hub) go unaddressed and sometimes worsen. Add the regulatory-arbitrage layer — the same molecule prescription-gated in London and candy-aisled in Los Angeles — and the hub doubles as a case study in how oversight architecture, not pharmacology, determines what childhood exposure looks like. The corrective is not panic-and-ban; it is the boring stack: verify, dose low, time right, treat behaviourally first, store like medicine.

For ordinary child sleep problems: behavioural treatment first — fixed wake time, consistent routine, screens out of the bedroom and off an hour before bed, morning light — because it has the best evidence and treats the cause; most “melatonin responders” are responding to the routine that came with the gummy. If melatonin is used: ideally with paediatric advice (mandatory anyway in prescription countries), for the indications with evidence (autism/ADHD sleep onset, circadian phase problems, short-term onset insomnia), at the lowest dose (0.5-1 mg is a rational start; more is rarely better for timing), given 30-60 minutes before an age-appropriate bedtime, verified brands only (third-party tested — USP or equivalent — given the 0-347% content lottery), and time-limited with periodic off-trials rather than indefinite nightly candy. Non-negotiables: child-resistant storage up and away (gummies read as sweets — the 11,000 ED visits were mostly toddlers self-serving), never framed to the child as candy, and doses in teenagers audited against the caffeine hub's afternoon habits, which cause much of what melatonin is bought to fix. And if a child needs a nightly substance to sleep indefinitely: that is a paediatric consultation, not a subscription.